Neuroendocrine Tumors (NET) Conference – Dijon | APTED Event
- The European Neuroendocrine Tumor Society (ENETS) is actively engaged in advancing research and improving care for neuroendocrine tumors (NETs), with a series of events and recent data releases...
- ENETS recently announced the abstract title list for its 2026 conference is now available online, offering a preview of the topics to be discussed by researchers and clinicians.
- A virtual General Assembly is scheduled for April 8, 2026, at 17:00 CEST, for all ENETS members.
European Society for Neuroendocrine Tumors Hosts Events, Shares Research Updates
The European Neuroendocrine Tumor Society (ENETS) is actively engaged in advancing research and improving care for neuroendocrine tumors (NETs), with a series of events and recent data releases signaling progress in the field. Founded in 2004, ENETS has grown to over 1,500 members representing a diverse range of medical disciplines.
ENETS recently announced the abstract title list for its 2026 conference is now available online, offering a preview of the topics to be discussed by researchers and clinicians. The society also highlighted grant winners and upcoming sessions as part of a sneak peek leading up to the event. News released on February 9, 2026, detailed upcoming sessions and satellite events.
A virtual General Assembly is scheduled for , at , for all ENETS members. Members are reminded to ensure their membership fees are current to participate. Access details will be provided closer to the meeting date.
Beyond the annual conference and general assembly, ENETS is facilitating collaboration through the CoE Exchange 2026, taking place on in Kraków. This event provides a platform for Centers of Excellence to connect and share insights. Also on in Kraków, ENETS will host a Women in NET (WiN) Meeting, designed for networking and collaboration among women in the field.
Recent research presented at the ENETS 2025 conference in Kraków, Poland, showcased positive topline Phase 3 data from the COMPETE trial. ITM Isotope Technologies Munich SE presented the findings, which focused on n.c.a. 177Lu-edotreotide (ITM-11), a targeted radiopharmaceutical therapy for patients with Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The trial met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) compared to everolimus.
According to study investigator Jaume Capdevila, MD, PhD, of Vall d’Hebron University Hospital in Barcelona, the median PFS was 23.9 months for patients receiving n.c.a. 177Lu-edotreotide, compared to 14.1 months for those receiving everolimus (p value=0.022). Dr. Capdevila stated that the COMPETE trial is the first pivotal study comparing a radiopharmaceutical drug candidate to a targeted molecular therapy without the routine use of accompanying somatostatin analogues in this patient population. ITM plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in 2025.
For patients and families affected by neuroendocrine cancer, resources and events are available through organizations like the Neuroendocrine Tumor Research Foundation (NETRF). These events feature researchers, experts, and fellow patients sharing information on the latest tests and treatments. The NETRF also facilitates fundraising events to support research efforts. A recording of the 2025 “Know Your NETs” conference is currently available.
ENETS provides accredited educational programs, including conferences, webinars, and e-learning modules, designed for healthcare professionals. The society’s mission is to raise awareness, advance research, and foster collaboration in the NET field, extending its reach beyond Europe to a global community dedicated to improving NET diagnosis, treatment, and care.